Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595699 · ClinicalTrials.gov registry record · Phase 4
Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy
A Phase 4 study of Major Depression and Temporal Lobe Epilepsy, sponsored by Conrad, Erich J., M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT00595699: Completed Phase 4 study of Major Depression and Temporal Lobe Epilepsy, sponsored by Conrad, Erich J., M.D..
NCT00595699 is a Phase 4 study of Major Depression and Temporal Lobe Epilepsy that has completed, run by Conrad, Erich J., M.D.. The registered enrollment target is 8 participants, below the 327-participant average among 28 other Major Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00595699, a Phase 4 study of Major Depression and Temporal Lobe Epilepsy, has completed, sponsored by Conrad, Erich J., M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy. The purpose of the study is to measure the severity and change in depressive and anxiety symptoms after 10 weeks of study treatment with escitalopram or placebo as measured by certain rating scales and questionnaires. In addition, the study will measure the frequency of seizures using a patient diary during the study. Finally, the study will assess the change in the quality of life using rating scales.
Conditions Studied
Interventions
- DRUG placebo
- DRUG escitalopram
Study Locations (1)
Louisiana
- LSU Anxiety and Mood Disorders Clinic - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 4 |
What the finished NCT00595699 record still lists
NCT00595699 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 327-participant average among 28 other Major Depression trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Major Depression appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00595699 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT00595699 about?
NCT00595699 is a clinical study titled "Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy". This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy. The purpose of the study is to measure the severity and change in depressive and anxiety symptoms after 10 weeks of study treatment with escitalopram ...
What is the current status of trial NCT00595699?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2006-11. Estimated completion is 2009-12.
What conditions does trial NCT00595699 study?
This clinical trial studies the following conditions: Major Depression, Temporal Lobe Epilepsy.
What interventions are being tested in trial NCT00595699?
The interventions under investigation include: placebo (DRUG), escitalopram (DRUG).
Who is sponsoring clinical trial NCT00595699?
This trial is sponsored by Conrad, Erich J., M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00595699 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00595699's enrollment target sits among peer trials
8 28th of 28 higher than 1 of 28 other Major Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.
COMPLETED · Phase 4
-
Preventing Depression Recurrence in Diabetes
COMPLETED · Phase 4
-
Pharmacotherapy in Depression With Panic Spectrum
COMPLETED · Phase 4
-
Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram
COMPLETED · Phase 4
-
Prozac Treatment of Major Depression: Discontinuation Study
COMPLETED · Phase 4
-
Thyroid Medication and Antidepressants for Treating Major Depression
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia